Tags: 
Dec 23, 2014– Cambridge-based ImmusanT Inc. has raised $12 million in financing for its celiac-fighting immunotherapy Nexvax2 and its two celiac diagnostic tools, funding that will progress the clinical trials and development of both diagnostics and the immunotherapy.
Previously, the company raised $1 million to kick off operations from an angel investor, than raised $20 million in 2011.
May 21, 2019 – ImmusanT Presents Early Evidence Supporting its Lead Therapeutic Vaccine Candidate During the Digestive Disease Week Annual Conference 2019:
1. This study found that serum IL-2 elevation is highly specific and sensitive to gluten challenge suggesting that IL-2 has diagnostic utility in celiac disease patients.
2. SC versus ID delivery provided a higher peptide exposure and shown to induce non-responsiveness to the high doses of gluten-derived immunogenic peptides.
The studies presented at this year’s DDW conference make a strong case demonstrating the Nexvax2 therapeutic vaccine has great potential to make a difference in the lives of celiac disease patients. Indeed, data show a link between elevated serum IL-2 levels and gluten exposure in people with celiac disease, and early evidence that Nexvax2 has the potential to induce immune tolerance to gluten.
http://www.immusant.com/ImmusanT%20DDW%20Post%20Conf%20-%2021May19%20FINAL.pdf
June 25, 2019 – ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Celiac Disease
The results from an interim analysis revealed Nexvax2 did not provide statistically meaningful protection from exposure for celiac disease patients when compared with placebo. Similar to earlier Phase 1 results, Nexvax2 was found to be safe and generally well tolerated.
http://www.immusant.com/ImmusanT%20Nexvax2%20P2%20-%2025Jun19%20Final.pdf
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.